Bristol Myers Squibb Drug Misses Endpoint in Crohn's Disease Trial
By Ben Glickman
Bristol Myers Squibb's said a trial of its drug Zeposia to treat Crohn's disease didn't meet its goals, potentially squashing a new indication for the treatment.
The pharmaceutical giant said on Thursday the trial failed to reach its primary endpoint of clinical remission for moderate to severe active Crohn's disease at week 12, based on an initial analysis. Bristol Myers Squibb said it would complete a full evaluation of the trial data and share results with the scientific community.
Zeposia is approved by regulators for treatment of multiple sclerosis and ulcerative colitis.
Crohn's is a chronic inflammatory bowel disease which affects the digestive tract.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
March 28, 2024 16:42 ET (20:42 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
How the Tokyo Stock Exchange Is Pushing for Better Capital Allocation
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom
-
Albemarle Earnings: We Expect Improved Results In the Rest of Year Following Cyclically Low Profits
-
Novo Nordisk Earnings: Raised Fair Value Estimate Still a Contrast to Market Overenthusiasm
-
After Earnings, Is Verizon Stock a Buy, a Sell, or Fairly Valued?
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting